{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:57:27Z","timestamp":1784228247434,"version":"3.55.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Host-directed therapies (HDTs) enhance the host response to tuberculosis (TB) infection to reduce disease severity. For instance, the manipulation of lipid mediator production diminishes the hyperactive immune response which is a known pathological feature of TB that generates lung tissue damage. Non-steroidal anti-inflammatory drugs (NSAIDs) and omega-3 long-chain polyunsaturated fatty acids (n-3 LCPUFA) are examples of such HDTs. In this mini-review, we recapitulate the literature available on the effects of NSAIDs and n-3 LCPUFA in TB as well as the immunological pathways underpinning these effects. Many NSAIDs have a great deal of data describing their effects and safety and in many jurisdictions are inexpensive, and sold over the counter in neighborhood convenience stores and supermarkets. The potential benefits of NSAIDs in TB are well-documented in pre-clinical studies. The reduction of pro-inflammatory lipid mediator production by inhibiting cyclooxygenase (COX) pathways with NSAIDs has been found to improve lung histopathology, bacterial control, and survival. Additionally, n-3 LCPUFA and its novel bioactive metabolites produced by COX and lipoxygenase (LOX) have been identified as safe and effective pro-resolving and antibacterial pharmaconutrients. Nevertheless, heterogeneous results have been reported in pre-clinical TB studies. Recently, the importance of the correct timing of NSAIDs and n-3 LCPUFA administration in TB has also been highlighted. This mini-review will provide a better understanding of the potential contribution of these therapies toward reducing inflammatory lung damage and improving bactericidal activity, especially during later stages of TB infection. It further highlights that clinical trials are required to confirm benefit and safety in TB patients.<\/jats:p>","DOI":"10.3389\/fimmu.2021.623941","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T04:40:27Z","timestamp":1615524027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The Manipulation of the Lipid Mediator Metabolism as Adjunct Host-Directed Therapy in Tuberculosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Arista","family":"Nienaber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank E. A.","family":"Hayford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebrahim","family":"Variava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Martinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"key":"B1","volume-title":"Global Tuberculosis Report","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.micpath.2019.03.003","article-title":"Host-directed therapies to combat tuberculosis and associated non-communicable diseases","volume":"130","author":"Baindara","year":"2019","journal-title":"Microb Pathogen."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4014\/jmb.1705.05032","article-title":"Host-directed therapeutics as a novel approach for tuberculosis treatment","volume":"27","author":"Kim","year":"2017","journal-title":"J Microbiol Biotechnol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000490478","article-title":"Host directed therapies for tuberculosis: futures strategies for an ancient disease","volume":"63","author":"Palucci","year":"2018","journal-title":"Chemotherapy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.3389\/fmicb.2018.02603","article-title":"The immune mechanisms of lung parenchymal damage in tuberculosis and the role of host-directed therapy","volume":"9","author":"Stek","year":"2018","journal-title":"Front Microbiol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/path.5407","article-title":"Effects of host-directed therapies on the pathology of tuberculosis","volume":"250","author":"Tsenova","year":"2020","journal-title":"J Pathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"ofz257","DOI":"10.1093\/ofid\/ofz257","article-title":"Plasma pro-inflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis","volume":"6","author":"Kumar","year":"2019","journal-title":"Open Forum Infect Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40169-016-0119-0","article-title":"Adult pulmonary tuberculosis as a pathological manifestation of hyperactive antimycobacterial immune response","volume":"5","author":"Kumar","year":"2016","journal-title":"Clin Transl Med."},{"key":"B11","first-page":"136","article-title":"Metabolism of polyunsaturated fatty acids by cells of the immune system.","volume-title":"Fatty Acid Metabolism","author":"Calder","year":"2018"},{"key":"B12","doi-asserted-by":"publisher","first-page":"13028","DOI":"10.1096\/fj.201901590R","article-title":"Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis","volume":"33","author":"Colas","year":"2019","journal-title":"FASEB J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.it.2013.10.008","article-title":"Lipid mediators in immune dysfunction after severe inflammation","volume":"35","author":"Fullerton","year":"2014","journal-title":"Trends Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3389\/fimmu.2017.00772","article-title":"Non-steroidal anti-inflammatory drugs as host-directed therapy for tuberculosis: a systematic review","volume":"8","author":"Kroesen","year":"2017","journal-title":"Front Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3389\/fimmu.2018.00798","article-title":"A beneficial effect of low-dose aspirin in a murine model of active tuberculosis","volume":"9","author":"Kroesen","year":"2018","journal-title":"Front Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12931-020-01488-9","article-title":"The effects of anti-inflammatory agents as host-directed adjunct treatment of tuberculosis in humans: a systematic review and meta-analysis","volume":"21","author":"Hayford","year":"2020","journal-title":"Resp Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.3390\/nu12092897","article-title":"Omega-3 fatty acid and iron supplementation alone, but not in combination, lower inflammation and anemia of infection in mycobacterium tuberculosis-infected mice","volume":"12","author":"Nienaber","year":"2020","journal-title":"Nutrients."},{"key":"B18","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nri3259","article-title":"The immunological life cycle of tuberculosis","volume":"12","author":"Ernst","year":"2012","journal-title":"Nature Rev Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1128\/IAI.71.12.7099-7108.2003","article-title":"Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity","volume":"71","author":"Kaplan","year":"2003","journal-title":"Infect Immun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/imr.12259","article-title":"The onset of adaptive immunity in the mouse model of tuberculosis and the factors that compromise its expression","volume":"264","author":"Robinson","year":"2015","journal-title":"Immunol rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00281-015-0531-3","article-title":"Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis","volume":"38","author":"Dorhoi","year":"2016","journal-title":"Semin Immunopathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.immuni.2007.12.010","article-title":"Macrophage and T cell dynamics during the development and disintegration of mycobacterial granulomas","volume":"28","author":"Egen","year":"2008","journal-title":"Immunity."},{"key":"B23","doi-asserted-by":"publisher","first-page":"808","DOI":"10.5588\/ijtld.14.0983","article-title":"Chronic airway obstruction after successful treatment of tuberculosis and its impact on quality of life","volume":"19","author":"De La Mora","year":"2015","journal-title":"Int J Tuberc Lung Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12890-016-0213-5","article-title":"Lung functions among patients with pulmonary tuberculosis in Dar es Salaam\u2013a cross-sectional study","volume":"16","author":"Manji","year":"2016","journal-title":"BMC Pulm Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"e0161176","DOI":"10.1371\/journal.pone.0161176","article-title":"A systematic review of the prevalence and pattern of imaging defined post-TB lung disease","volume":"11","author":"Meghji","year":"2016","journal-title":"PLoS ONE."},{"key":"B26","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.bjid.2015.06.005","article-title":"Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients","volume":"19","author":"Nihues","year":"2015","journal-title":"Braz J Infect Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1055\/s-2006-946581","article-title":"Frequency and morphology of tuberculosis in autopsies: increase of active forms","volume":"131","author":"Theegarten","year":"2006","journal-title":"Dtsch Med Wochenschr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nature Rev Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1021\/cr200085w","article-title":"Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention","volume":"111","author":"Dennis","year":"2011","journal-title":"Chem Rev."},{"key":"B30","doi-asserted-by":"publisher","first-page":"8677","DOI":"10.4049\/jimmunol.181.12.8677","article-title":"Rapid appearance of resolvin precursors in inflammatory exudates: novel mechanisms in resolution","volume":"181","author":"Kasuga","year":"2008","journal-title":"J Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mam.2017.08.002","article-title":"New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration","volume":"64","author":"Serhan","year":"2017","journal-title":"Mol Aspects Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbalip.2014.08.010","article-title":"Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance","volume":"1851","author":"Calder","year":"2015","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids."},{"key":"B33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1172\/JCI200113416","article-title":"Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes","volume":"108","author":"Tilley","year":"2001","journal-title":"J Clin Invest."},{"key":"B34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.coi.2013.05.005","article-title":"Inflammation in tuberculosis: interactions, imbalances and interventions","volume":"25","author":"Kaufmann","year":"2013","journal-title":"Curr Opin Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1021\/cr100396c","article-title":"Resolvins and protectins in inflammation resolution","volume":"111","author":"Serhan","year":"2011","journal-title":"Chem Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/MOL.0000000000000262","article-title":"n-3 Fatty acid supplementation and proresolving mediators of inflammation","volume":"27","author":"Barden","year":"2016","journal-title":"Curr Opin Lipidol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1194\/jlr.P031260","article-title":"Evaluation of suppressive and pro-resolving effects of EPA and DHA in human primary monocytes and T-helper cells","volume":"54","author":"Jaudszus","year":"2013","journal-title":"J Lipid Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.clnu.2015.04.004","article-title":"A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease","volume":"35","author":"Mas","year":"2016","journal-title":"Clin Nutr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.4049\/jimmunol.0900477","article-title":"Effects of low-dose aspirin on acute inflammatory responses in humans","volume":"183","author":"Morris","year":"2009","journal-title":"J Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1096\/fj.201601222R","article-title":"Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms","volume":"31","author":"Serhan","year":"2017","journal-title":"FASEB J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3389\/fcimb.2019.00335","article-title":"Plasma eicosanoid levels in tuberculosis and tuberculosis-diabetes co-morbidity are associated with lung pathology and bacterial burden","volume":"9","author":"Kumar","year":"2019","journal-title":"Front Cell Infect Microbiol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"154759","DOI":"10.1016\/j.cyto.2019.154759","article-title":"Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: a prospective cohort study","volume":"123","author":"Vinhaes","year":"2019","journal-title":"Cytokine."},{"key":"B43","doi-asserted-by":"publisher","first-page":"106398","DOI":"10.1016\/j.prostaglandins.2019.106398","article-title":"Lipid mediators of inflammation and resolution in individuals with tuberculosis and tuberculosis-Diabetes","volume":"147","author":"Shivakoti","year":"2020","journal-title":"Prostagl Other Lipid Mediat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"165574","DOI":"10.1016\/j.bbadis.2019.165574","article-title":"Eicosanoid pathway on host resistance and inflammation during Mycobacterium tuberculosis infection is comprised by LTB4 reduction but not PGE2 increment","volume":"1866","author":"Sorgi","year":"2020","journal-title":"BBA-Mol Basis Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrmicro2387","article-title":"Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy?","volume":"8","author":"Behar","year":"2010","journal-title":"Nat Rev Microbiol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"C39","DOI":"10.1152\/ajpcell.00024.2014","article-title":"Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue","volume":"307","author":"Colas","year":"2014","journal-title":"Amer J Physiol-Cell Physiol."},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/2020.08.04.236257","article-title":"Immunosuppressive role of PGE2 during human tuberculosis","author":"Pellegrini","year":"2020","journal-title":"bioRxiv."},{"key":"B48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/infdis\/jit153","article-title":"Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment","volume":"208","author":"Ivanyi","year":"2013","journal-title":"J Infect Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature13489","article-title":"Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk","volume":"511","author":"Mayer-Barber","year":"2014","journal-title":"Nature."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e108854","DOI":"10.1371\/journal.pone.0108854","article-title":"Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study","volume":"9","author":"Frediani","year":"2014","journal-title":"PLoS ONE."},{"key":"B51","doi-asserted-by":"publisher","first-page":"105694","DOI":"10.1016\/j.intimp.2019.105694","article-title":"Resolvin D1 (RvD1) and maresin 1 (Mar1) contribute to human macrophage control of M. tuberculosis infection while resolving inflammation","volume":"74","author":"Ruiz","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"29","DOI":"10.12703\/P7-29","article-title":"Duality of lipid mediators in host response against Mycobacterium tuberculosis: good cop, bad cop","volume":"7","author":"Dietzold","year":"2015","journal-title":"F1000Prime Rep."},{"key":"B53","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/imr.12249","article-title":"Cytokine and lipid mediator networks in tuberculosis","volume":"264","author":"Mayer-Barber","year":"2015","journal-title":"Immunol Rev."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(02)01828-9","article-title":"Anti-inflammatory effects of aspirin and sodium salicylate","volume":"447","author":"Amann","year":"2002","journal-title":"Euro J Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/jac\/dkl486","article-title":"Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis","volume":"59","author":"Byrne","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0926-6917(95)00011-9","article-title":"Chronopharmacological study of acetylsalicylic acid in mice","volume":"293","author":"Ohdo","year":"1995","journal-title":"Euro J Pharmacol Environ Toxicol Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/infdis\/jit152","article-title":"Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis","volume":"208","author":"Vilaplana","year":"2013","journal-title":"J Infect Dis."},{"key":"B58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.tube.2013.09.004","article-title":"Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis","volume":"94","author":"Marzo","year":"2014","journal-title":"Tuberculosis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cell.2011.12.023","article-title":"Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections","volume":"148","author":"Tobin","year":"2012","journal-title":"Cell."},{"key":"B60","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1128\/AAC.01145-06","article-title":"Aspirin antagonism in isoniazid treatment","volume":"51","author":"Byrne","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"B61","first-page":"506","article-title":"T-cell lung granulomas induced by sepharose-coupled Mycobacterium tuberculosis protein antigens: immunosuppressive phenomena reversed with cyclophosphamide and indomethacin","volume":"86","author":"Hernandez-Pando","year":"1995","journal-title":"Immunology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1938-8","article-title":"The COX-inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection","volume":"16","author":"Tonby","year":"2016","journal-title":"BMC Infect Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1365-2249.1990.tb05192.x","article-title":"Role of antigen-presenting cells in variation in immunogenicity of mycobacteria","volume":"79","author":"Shroff","year":"1990","journal-title":"Clin Exp Immunol."},{"key":"B64","first-page":"922","article-title":"In vitro and in vivo antimycobacterial activity of antiinflammatory drug, diclofenac sodium","volume":"42","author":"Dutta","year":"2004","journal-title":"Indian J Exp Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijantimicag.2007.04.016","article-title":"Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice","volume":"30","author":"Dutta","year":"2007","journal-title":"Int J Antimicrob Agents."},{"key":"B66","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/AAC.00735-10","article-title":"Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor","volume":"55","author":"Kalle","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.bmc.2015.03.041","article-title":"Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore","volume":"23","author":"Salunke","year":"2015","journal-title":"Bioorg Med Chem."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-019-0530-3","article-title":"Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice","volume":"2","author":"Mortensen","year":"2019","journal-title":"Commun Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1046\/j.1365-2567.2002.01403.x","article-title":"The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis","volume":"106","author":"Rangel Moreno","year":"2002","journal-title":"Immunology."},{"key":"B70","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni.1758","article-title":"Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair","volume":"10","author":"Divangahi","year":"2009","journal-title":"Nat Immunol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1172\/JCI23949","article-title":"Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase\u2013dependent lipoxin production","volume":"115","author":"Bafica","year":"2005","journal-title":"J Clin Invest."},{"key":"B72","first-page":"400","article-title":"Activation of latent tuberculosis by nonsteroidal anti-inflammatory agents","volume":"122","author":"Brennan","year":"1980","journal-title":"Can Med Assoc J."},{"key":"B73","first-page":"21","article-title":"Latent tuberculosis and anti-inflammatory agents","volume":"126","author":"Brennan","year":"1982","journal-title":"Can Med Assoc J."},{"key":"B74","first-page":"275","article-title":"Tuberculosis and nonsteroidal anti-inflammatory drugs","volume":"130","author":"Tomasson","year":"1984","journal-title":"Can Med Assoc J."},{"key":"B75","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12890-017-0425-3","article-title":"Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study","volume":"17","author":"Wu","year":"2017","journal-title":"BMC Pulm Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/art.24476","article-title":"Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada","volume":"61","author":"Brassard","year":"2009","journal-title":"Arthritis Care Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-31590-4","article-title":"Adjunctive use of celecoxib with anti-tuberculosis drugs: evaluation in a whole-blood bactericidal activity model","volume":"8","author":"Naftalin","year":"2018","journal-title":"Sci Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"898","DOI":"10.7326\/0003-4819-60-5-898","article-title":"Inhibition of pyrazinamide hyperuricemia by small doses of acetylsalicylic acid","volume":"60","author":"Petty","year":"1964","journal-title":"Ann Intern Med."},{"key":"B79","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0041-3879(79)90051-5","article-title":"Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration","volume":"60","author":"Horsfall","year":"1979","journal-title":"Tubercle."},{"key":"B80","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2010.03.025","article-title":"Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial","volume":"293","author":"Misra","year":"2010","journal-title":"J Neurol Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"e33478","DOI":"10.7554\/eLife.33478.026","article-title":"A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults","volume":"7","author":"Mai","year":"2018","journal-title":"Elife."},{"key":"B82","doi-asserted-by":"publisher","first-page":"e10878","DOI":"10.1371\/journal.pone.0010878","article-title":"Incorporation of a dietary omega 3 fatty acid impairs murine macrophage responses to mycobacterium","volume":"5","author":"Bonilla","year":"2010","journal-title":"PLoS ONE."},{"key":"B83","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1086\/650344","article-title":"Transgenic mice enriched in omega-3 fatty acids are more susceptible to pulmonary tuberculosis: impaired resistance to tuberculosis in fat-1 mice","volume":"201","author":"Bonilla","year":"2010","journal-title":"J Infect Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.3945\/jn.108.093740","article-title":"Dietary polyunsaturated fatty acids modulate resistance to Mycobacterium tuberculosis in guinea pigs","volume":"138","author":"McFarland","year":"2008","journal-title":"J Nutr."},{"key":"B85","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0026-0495(97)90003-2","article-title":"Influence of n-6 and n-3 polyunsaturated fatty acids on the resistance to experimental tuberculosis","volume":"46","author":"Paul","year":"1997","journal-title":"Metabolism."},{"key":"B86","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.imlet.2004.06.007","article-title":"Dietary 18: 3\u03c93 influences immune function and the tissue fatty acid response to antigens and adjuvant","volume":"95","author":"Bazinet","year":"2004","journal-title":"Immunol Lett."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.micinf.2008.08.004","article-title":"Effects of omega-3 and-6 fatty acids on Mycobacterium tuberculosis in macrophages and in mice","volume":"10","author":"Jordao","year":"2008","journal-title":"Microbes Infect."},{"key":"B88","first-page":"854","article-title":"Role of combined zinc, vitamin A, and fish oil supplementation in childhood tuberculosis","volume":"44","author":"Nenni","year":"2013","journal-title":"Southeast Asian J Trop Med Public Health."},{"key":"B89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.30742\/jikw.v7i1.313","article-title":"The role of zinc sulphate and omega 3 on the improvement of weight and speed conversion conversion on tuberculosis parent patients at Surabaya Park Hospital, 2015","volume":"7","author":"Durry","year":"2018","journal-title":"J Ilm Kedokt Wijaya Kusuma."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1093\/jac\/dkaa307","article-title":"Carprofen elicits pleiotropic mechanisms of bactericidal action with the potential to reverse antimicrobial drug resistance in tuberculosis","volume":"75","author":"Maitra","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"B91","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2007.04.018","article-title":"Potential management of resistant microbial infections with a novel non-antibiotic: the anti-inflammatory drug diclofenac sodium","volume":"30","author":"Dutta","year":"2007","journal-title":"Int J Antimicrob Agents."},{"key":"B92","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1473-3099(12)70321-3","article-title":"Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Critchley","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1042\/BST20160474","article-title":"Omega-3 fatty acids and inflammatory processes: from molecules to man","volume":"45","author":"Calder","year":"2017","journal-title":"Biochem Soc Trans."},{"key":"B94","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3945\/ajcn.112.041343","article-title":"Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish\u2013","volume":"96","author":"Browning","year":"2012","journal-title":"Am J Clin Nutr."},{"key":"B95","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.prostaglandins.2013.05.001","article-title":"Eicosanoid biosynthesis during mucociliary and mucous metaplastic differentiation of bronchial epithelial cells","volume":"106","author":"Jakiela","year":"2013","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"B96","doi-asserted-by":"publisher","first-page":"18S","DOI":"10.1177\/0148607115595980","article-title":"Functional roles of fatty acids and their effects on human health","volume":"39","author":"Calder","year":"2015","journal-title":"J Parenter Enter Nutr."},{"key":"B97","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s11745-000-0583-1","article-title":"Effect of low-to-moderate amounts of dietary fish oil on neutrophil lipid composition and function","volume":"35","author":"Healy","year":"2000","journal-title":"Lipids."},{"key":"B98","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/nbu.12404","article-title":"How does polyunsaturated fatty acid biosynthesis regulate T-lymphocyte function?","volume":"44","author":"Fielding","year":"2019","journal-title":"Nutr Bull."},{"key":"B99","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature11042","article-title":"Infection regulates pro-resolving mediators that lower antibiotic requirements","volume":"484","author":"Chiang","year":"2012","journal-title":"Nature."},{"key":"B100","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/mi.2017.36","article-title":"Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection","volume":"11","author":"Codagnone","year":"2018","journal-title":"Muc Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1056\/NEJMcibr1511280","article-title":"Resolvin infectious inflammation by targeting the host response","volume":"373","author":"Lee","year":"2015","journal-title":"N Engl J Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/nature08541","article-title":"Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis","volume":"461","author":"Spite","year":"2009","journal-title":"Nature."},{"key":"B103","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/BF01739016","article-title":"Influence of dietary (n-3)-polyunsaturated fatty acids on leukotriene B 4 and prostaglandin E 2 synthesis and course of experimental tuberculosis in guinea pigs","volume":"22","author":"Mayatepek","year":"1994","journal-title":"Infection."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.623941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T04:40:36Z","timestamp":1615524036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.623941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2021.623941"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.623941","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"article-number":"623941"}}